merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>Safety risks and modest benefits not outweighing them</answer>
<question_number>2</question_number>
<answer>It might discourage patients from participating in trials for better treatments and slow progress</answer>
<question_number>3</question_number>
<answer>No correlation</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>Patients can stop after amyloid is cleared</answer>
<question_number>6</question_number>
<answer>It might discourage patients from participating in trials for better treatments</answer>
<question_number>7</question_number>
<answer>Patients can stop after amyloid is cleared</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly than those with high levels</answer>